Boston Scientific (NYSE:BSX) reported fourth-quarter results that topped analyst estimates, driven by a double-digit surge in its cardiovascular division and a string of regulatory wins that are reshaping its competitive landscape.
The Marlborough, Massachusetts-based manufacturer said Wednesday that fourth-quarter net sales rose 15.9% to $5.286 billion.
On an organic basis—which excludes the impact of currency and recent deal-making—sales grew 12.7%.
The performance was anchored by the Cardiovascular segment, which saw a reported revenue increase of 18.2%, led by the continued global rollout of the FARAPULSE pulsed field ablation (PFA) system.
Adjusted earnings for the quarter were 80 cents per share, surpassing the company’s own guidance range of 77 to 79 cents.
For the full year 2025, Boston Scientific delivered $20.074 billion in net sales, marking a nearly 20% increase from the prior year and underscoring its status as a top performer in the MedTech sector.
"2025 was another exceptional year where our team delivered differentiated innovation that enabled us to exceed our goals," CEO Mike Mahoney said in the statement.
The company is moving aggressively to maintain this momentum through a spree of strategic acquisitions.